Erowid.org: Erowid Reference 8311 : Acute toxicity and withdrawal syndromes related to gamma-hydroxybutyrate (GHB) and its analogues gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) : Wood DM, Brailsford AD, Dargan PI

Erowid References Database

Wood DM, Brailsford AD, Dargan PI. “Acute toxicity and withdrawal syndromes related to gamma-hydroxybutyrate (GHB) and its analogues gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD)”. Drug Test Anal. 2011 May 6. <a name="ref">Wood DM, Brailsford AD, Dargan PI.</a> <a href="/references/8311">"Acute toxicity and withdrawal syndromes related to gamma-hydroxybutyrate (GHB) and its analogues gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD)"</a> <i>Drug Test Anal</i>. 2011 May 6.
Text Abstract (this page) Full Text - English (private) Show Articles by Wood DM Brailsford AD Dargan PI Article IDs Erowid RefID: 8311 PubMedID: 21548140 Collections Hofmann Collection MDMA Collection All References	Abstract Gamma-hydroxybutyrate (GHB) has been used as a recreational drug since the 1990s and over the last few years there has been increasing use of its analogues gamma-butyrolactone (GBL) and to a lesser extent 1,4-butanediol (1,4BD). This review will summarize the literature on the pharmacology of these compounds; the patterns and management of acute toxicity associated with their use; and the clinical patterns of presentation and management of chronic dependency associated with GHB and its analogues. Copyright © 2011 John Wiley & Sons, Ltd.
Comments and Responses to this Article #
Submit Comment

[ Cite HTML ]